Related Experiment Video
Updated: May 9, 2026
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Mining sarcomas by proteomics approaches: Ewing sarcoma on the spotlight
Carlos Mackintosh1, Juan Madoz-Gúrpide
1Molecular Pathology Program, Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca- CSIC, Salamanca, 37007, Spain. cmackintosh@usal.es
Abstract:
Sarcomas are a class of tumors defined by their mesenchymal origin that comprise very different neoplasms. Although some sarcomas harbor pathogenomic molecular alterations (i.e. specific balanced translocations and their associated chimeric fusion genes), others still lack an ultimate diagnostic tool, which could be of great interest as in some cases different sarcomas share a similar clinical manifestation. High throughput tools are contributing new ways to molecularly delineate the boundaries of each sarcoma subtype. Moreover, they are also shedding light into other research subjects of immediate concern: (i) the elucidation of the molecular targets of chimeric fusion proteins and their interactome; (ii) the discovery of new biomarkers and therapeutic targets; and (iii) the delineation of the response to therapeutic agents. Here we review the application of proteomics approaches to sarcomas, with special emphasis in Ewing sarcoma. Proteomics strategies offer the focus, the analytical potential, and the high throughput capabilities to decipher the hidden agenda of the biology of sarcomas, a knowledge that will surely be the subject of future patents intended to develop new diagnostic and therapeutic tools.
Insights
Proteomics advances sarcoma research by identifying molecular targets and biomarkers. This high-throughput approach aids in diagnosing diverse sarcomas and developing novel therapies, particularly for Ewing sarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Sarcomas are diverse tumors of mesenchymal origin with varying diagnostic clarity.
- Some sarcomas have identifiable molecular alterations, but others lack definitive diagnostic tools despite similar clinical presentations.
- High-throughput technologies are crucial for molecularly classifying sarcoma subtypes.
Purpose of the Study:
- To review the application of proteomics in understanding sarcoma biology.
- To highlight the potential of proteomics in discovering diagnostic biomarkers and therapeutic targets.
- To emphasize the role of proteomics in elucidating sarcoma subtype boundaries and treatment responses, with a focus on Ewing sarcoma.
Main Methods:
- Review of current literature on proteomics applications in sarcoma research.
- Focus on high-throughput proteomics strategies for molecular delineation.
- Analysis of proteomics' contribution to understanding chimeric fusion proteins and their interactome.
Main Results:
- Proteomics offers high-throughput capabilities for molecularly defining sarcoma subtypes.
- Proteomics aids in identifying molecular targets of chimeric fusion proteins.
- Proteomics facilitates the discovery of new biomarkers and therapeutic targets for sarcomas.
Conclusions:
- Proteomics provides essential analytical power to decipher sarcoma biology.
- This knowledge is vital for developing innovative diagnostic and therapeutic tools for sarcomas.
- Future patents are anticipated based on proteomics-driven insights into sarcoma pathogenesis and treatment.
